HomeMarket NewsImpella Left Sided Blood Pumps Recall Rocks Johnson & Johnson Market

Impella Left Sided Blood Pumps Recall Rocks Johnson & Johnson Market

Actionable Trade Ideas

always free

Impella Pump Photo via JNJ

In a stunning revelation, Johnson & Johnson’s Abiomed unit announced a recall of its Impella Left Sided Blood Pumps due to a looming peril – the risk of perforating the wall of the left ventricle in the heart.

The Impella device, during critical operations, may inadvertently slice through this vital heart chamber’s membrane, unleashing a cascade of dire consequences.

The fallout from using the implicated Impella pumps is harrowing, with potential outcomes ranging from left ventricle perforation or free wall rupture to hypertension, impaired blood flow, and even fatalities.

A staggering tally of 129 severe injuries, including a grim count of 49 recorded deaths, serves to underscore the gravity of the situation sparked by the device’s design flaw.

In medical settings, Impella Left Sided Blood Pumps are deployed for transiently bolstering the heart’s pumping chambers, or ventricles, during high-stakes catheter-based procedures termed percutaneous coronary interventions (PCI).

Moreover, these pumps are instrumental in scenarios of acute cardiogenic shock arising within a 48-hour window post a severe heart attack, open-heart surgery, or when the heart’s efficacy is compromised by cardiomyopathy.

The rationale behind Impella therapy hinges on alleviating the ventricles’ workload and propping up the circulatory system, affording the heart the critical respite necessary for recuperation.

Amid the recall brouhaha, the FDA clarified that this move constitutes a corrective action rather than an outright product withdrawal, with Johnson & Johnson promptly dispatching revised warning missives to impacted consumers.

In a bid to rectify the situation, the medical apparatus manufacturer initiated the recall protocol on December 27, 2023, pulling back a staggering 66,390 devices across the American landscape. These recalled units had been disseminated between October 10, 2021, and October 10, 2023, amplifying the scale of the purge.

The specter of the Impella Left Sided Blood Pumps recall looms large over Johnson & Johnson, a conglomerate that swallowed Abiomed in 2022 for a princely sum of $16.6 billion, translating to an upfront payment of $380.00 per share in cash.

Impact on Trading: Market data shows JNJ shares inching up by a modest 0.28% to $156.20 at the latest check on Thursday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.